Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
Crossref DOI link: https://doi.org/10.1007/s12272-022-01385-3
Published Online: 2022-05-22
Published Print: 2022-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ali, Faraat http://orcid.org/0000-0002-1438-4223
Neha, Kumari
Chauhan, Garima
Text and Data Mining valid from 2022-05-01
Version of Record valid from 2022-05-01
Article History
Received: 9 October 2021
Accepted: 17 May 2022
First Online: 22 May 2022
Declarations
:
: The authors declare there is no conflict of interest.